Literature DB >> 22922764

A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge.

Rebecca J Grant-Klein1, Nicole M Van Deusen, Catherine V Badger, Drew Hannaman, Lesley C Dupuy, Connie S Schmaljohn.   

Abstract

We evaluated the immunogenicity and protective efficacy of DNA vaccines expressing the codon-optimized envelope glycoprotein genes of Zaire ebolavirus, Sudan ebolavirus, and Marburg marburgvirus (Musoke and Ravn). Intramuscular or intradermal delivery of the vaccines in BALB/c mice was performed using the TriGrid™ electroporation device. Mice that received DNA vaccines against the individual viruses developed robust glycoprotein-specific antibody titers as determined by ELISA and survived lethal viral challenge with no display of clinical signs of infection. Survival curve analysis revealed there was a statistically significant increase in survival compared to the control groups for both the Ebola and Ravn virus challenges. These data suggest that further analysis of the immune responses generated in the mice and additional protection studies in nonhuman primates are warranted.

Entities:  

Keywords:  DNA vaccine; codon-optimized; ebola virus; electroporation; filovirus; marburg virus; mice

Mesh：

Substances：

Year:  2012        PMID： 22922764      PMCID： PMC3601145          DOI： 10.4161/hv.21873

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  13 in total

1.  Development and application of a flow cytometric potency assay for DNA vaccines.

Authors:  C V Badger; J D Richardson; R L Dasilva; M J Richards; M D Josleyn; L C Dupuy; J W Hooper; C S Schmaljohn
Journal:  Vaccine       Date:  2011-01-08       Impact factor: 3.641

2.  A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates.

Authors:  Lesley C Dupuy; Michelle J Richards; Barry Ellefsen; Lillian Chau; Alain Luxembourg; Drew Hannaman; Brian D Livingston; Connie S Schmaljohn
Journal:  Clin Vaccine Immunol       Date:  2011-03-30

3.  Epitopes involved in antibody-mediated protection from Ebola virus.

Authors:  J A Wilson; M Hevey; R Bakken; S Guest; M Bray; A L Schmaljohn; M K Hart
Journal:  Science       Date:  2000-03-03       Impact factor: 47.728

4.  Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates.

Authors:  Thomas W Geisbert; Michael Bailey; Joan B Geisbert; Clement Asiedu; Mario Roederer; Maria Grazia-Pau; Jerome Custers; Peter Jahrling; Jaap Goudsmit; Richard Koup; Nancy J Sullivan
Journal:  J Virol       Date:  2010-07-21       Impact factor: 5.103

5.  A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.

Authors:  M Bray; K Davis; T Geisbert; C Schmaljohn; J Huggins
Journal:  J Infect Dis       Date:  1998-09       Impact factor: 5.226

6.  Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus.

Authors:  Nicola Ternette; Bettina Tippler; Klaus Uberla; Thomas Grunwald
Journal:  Vaccine       Date:  2007-08-23       Impact factor: 3.641

Review 7.  DNA vaccines: ready for prime time?

Authors:  Michele A Kutzler; David B Weiner
Journal:  Nat Rev Genet       Date:  2008-10       Impact factor: 53.242

8.  Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus.

Authors:  Jenny Riemenschneider; Aura Garrison; Joan Geisbert; Peter Jahrling; Michael Hevey; Diane Negley; Alan Schmaljohn; John Lee; Mary Kate Hart; Lorna Vanderzanden; David Custer; Mike Bray; Albert Ruff; Bruce Ivins; Anthony Bassett; Cynthia Rossi; Connie Schmaljohn
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

9.  Development and characterization of a mouse model for Marburg hemorrhagic fever.

Authors:  Kelly L Warfield; Steven B Bradfute; Jay Wells; Loreen Lofts; Meagan T Cooper; D Anthony Alves; Daniel K Reed; Sean A VanTongeren; Christine A Mech; Sina Bavari
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

10.  Immunogenicity in mice and rabbits of DNA vaccines expressing woodchuck hepatitis virus antigens.

Authors:  Alain Luxembourg; Drew Hannaman; Ken Wills; Robert Bernard; Bud C Tennant; Stephan Menne; Paul J Cote
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641
View more
  23 in total

1.  Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.

Authors:  May S ElSherif; Catherine Brown; Donna MacKinnon-Cameron; Li Li; Trina Racine; Judie Alimonti; Thomas L Rudge; Carol Sabourin; Peter Silvera; Jay W Hooper; Steven A Kwilas; Nicole Kilgore; Christopher Badorrek; W Jay Ramsey; D Gray Heppner; Tracy Kemp; Thomas P Monath; Teresa Nowak; Shelly A McNeil; Joanne M Langley; Scott A Halperin
Journal:  CMAJ       Date:  2017-06-19       Impact factor: 8.262

2.  A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model.

Authors:  Rohan Keshwara; Katie R Hagen; Tiago Abreu-Mota; Amy B Papaneri; David Liu; Christoph Wirblich; Reed F Johnson; Matthias J Schnell
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

3.  Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses.

Authors:  Mallory Willet; Drishya Kurup; Amy Papaneri; Christoph Wirblich; Jay W Hooper; Steve A Kwilas; Rohan Keshwara; Andrew Hudacek; Stefanie Beilfuss; Grit Rudolph; Elke Pommerening; Adriaan Vos; Andreas Neubert; Peter Jahrling; Joseph E Blaney; Reed F Johnson; Matthias J Schnell
Journal:  J Infect Dis       Date:  2015-06-10       Impact factor: 5.226

4.  Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges.

Authors:  Rebecca J Grant-Klein; Louis A Altamura; Catherine V Badger; Callie E Bounds; Nicole M Van Deusen; Steven A Kwilas; Hong A Vu; Kelly L Warfield; Jay W Hooper; Drew Hannaman; Lesley C Dupuy; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.

Authors:  John J Suschak; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2019-10-07       Impact factor: 3.452

6.  Innate Molecular and Cellular Signature in the Skin Preceding Long-Lasting T Cell Responses after Electroporated DNA Vaccination.

Authors:  Lucille Adam; Nicolas Tchitchek; Biliana Todorova; Pierre Rosenbaum; Candie Joly; Candice Poux; Catherine Chapon; Anna-Lena Spetz; Mart Ustav; Roger Le Grand; Frédéric Martinon
Journal:  J Immunol       Date:  2020-05-08       Impact factor: 5.422

Review 7.  Ebola vaccines in clinical trial: The promising candidates.

Authors:  Yuxiao Wang; Jingxin Li; Yuemei Hu; Qi Liang; Mingwei Wei; Fengcai Zhu
Journal:  Hum Vaccin Immunother       Date:  2016-10-20       Impact factor: 3.452

Review 8.  Ebola virus vaccines: an overview of current approaches.

Authors:  Andrea Marzi; Heinz Feldmann
Journal:  Expert Rev Vaccines       Date:  2014-02-27       Impact factor: 5.217

9.  Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola.

Authors:  Devon J Shedlock; Jenna Aviles; Kendra T Talbott; Gary Wong; Stephan J Wu; Daniel O Villarreal; Devin Jf Myles; Maria A Croyle; Jian Yan; Gary P Kobinger; David B Weiner
Journal:  Mol Ther       Date:  2013-05-14       Impact factor: 11.454

Review 10.  Neglected filoviruses.

Authors:  Robin Burk; Laura Bollinger; Joshua C Johnson; Jiro Wada; Sheli R Radoshitzky; Gustavo Palacios; Sina Bavari; Peter B Jahrling; Jens H Kuhn
Journal:  FEMS Microbiol Rev       Date:  2016-06-05       Impact factor: 16.408
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.